BioXcel (BTAI): Price-to-Revenue Ratio

Brandmark of BioXcel Therapeutics Inc (BTAI)

BioXcel Therapeutics (BTAI) is shielded from macroeconomic shocks by stable demand for neuropsychiatric drugs. The company leverages AI technologies to repurpose legacy drugs, accelerating the path to profitability. Growth is driven by the rollout of Igalmi and new licenses. The price/sales ratio helps avoid overpaying at peaks, while the 2.90 value characterizes this level on the chart.

BTAI BioXcel Therapeutics P/S Multiple (11/14/2022 - 09/19/2026)

Analytical breakdowns for BioXcel (BTAI)

- current quotes and average value forecast:
Market Price bioxceltherapeutics.com|BTAI - Price Target Chart
- stock exchange capitalization data:
Market Value BioXcel|BTAI - Total Company Value
- issuer book value statistics:
Net Asset Value per Share BioXcel Therapeutics|BTAI - Book Capitalization|Market Value to Equity Ratio bioxceltherapeutics.com|BTAI - Cumulative Company Assets
- issuer credit burden and liquidity indicators:
Debt to Capital BioXcel Therapeutics|BTAI - Long-Term Debt to Capital|Short-Term Debt to Equity BioXcel Therapeutics Corp|BTAI - Company Aggregate Debts|Debts to Net Assets BioXcel|BTAI - Company Long-Term Debt|Short-Term Debt BioXcel Therapeutics|Immediate Liquidity Ratio bioxceltherapeutics.com
- earnings and multiples data:
BTAI - Net Profit|Future Profit BioXcel Therapeutics|BTAI - P/E Multiple|Projected Price to Earnings Ratio BioXcel Therapeutics Inc|BTAI - Price/Earnings to Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization BioXcel|BTAI - Operating profit before deduction of amortization|Earnings per share for the trailing year BioXcel Therapeutics|BTAI - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months bioxceltherapeutics.com|BTAI - Earnings growth in current year|Expected earnings per share trend next year BioXcel Therapeutics
- issuer revenue and sales details:
BTAI - Revenue and Sales Volume|Company Expected Sales Volume bioxceltherapeutics.com|BTAI - Price-to-Revenue Ratio|Forward Price to Sales BioXcel
General company analysis:BTAI, bioxceltherapeutics.com
Mass-produced product of BioXcel Therapeutics Corp

The P/S ratio reflects the value of one dollar of annual sales by comparing market capitalization to actual revenue volume. Analyzing this revenue-based valuation metric allows for the identification of an overbought asset relative to its cash flow. The metric captures the gap between speculative price growth and fundamental results. For BioXcel Therapeutics (BTAI), steady demand for dementia medications makes this indicator a reliable filter against market volatility.

Competitors of BioXcel Therapeutics

JAZZ - Price to Sales|Price-to-Revenue Ratio Cytokinetics, Incorporated CYTK|PTC Therapeutics Inc - Price-to-Revenue Ratio|SRRK - Price-to-Revenue Ratio|Price to Sales Centessa Corp|DYN: P/S Multiple|Price-to-Revenue Multiple edgewisetx.com EWTX|Market Cap to Revenue RAPP|Price to Sales Alumis Inc ALMS|P/S Multiple ZVRA|Price-to-Revenue Ratio CTNM (Contineum Corp)|P/S Multiple LRMR (Larimar Therapeutics)|Price-to-Revenue Coefficient Capricor Therapeutics Inc. (CAPR)|TRDA - Price-to-Revenue Ratio|Price to Sales Channel Therapeutics Inc.|MNOV (medicinova.com) - Market Cap to Revenue|Market Cap to Revenue Ratio SER|PMN (ProMIS Neurosciences Inc.) - P/S Multiple|Market Cap to Revenue Apimeds (APUS)|P/S Multiple AEON|NLSP - Price to Sales|Price-to-Revenue Ratio Bionomics BNOX|fsdpharma.com - Price-to-Revenue Ratio|RETA: Market Cap to Revenue